Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Zoé L. E. van Kempen et al.|JAMA Neurology|2024Cited by 29
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)Wing Hee Fung, Eva Strijbis, Jop Mostert et al.|Journal of Neurology|2025Cited by 4